The effect of 2 and 3 years of Raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis
Kristine E. Ensrud(University of Minnesota), B. Mitlak(Eli Lilly (United States)), Ronald K. Knickerbocker, Jean‐Yves Reginster(King Saud University), H. A. P. Pols, Pierre Delmas, Steven T. Harris(Stanford Medicine), Robert R. Recker(Creighton University), Jonathan D. Adachi(St. Peter's Hospital), H Gennant, Richard Eastell(University of Sheffield), C. Gennari, N. H. Bjarnason(Center for Clinical & Basic Research), D Black
ORBi (University of Liège)
January 1, 1998
Cited by 21
Related Papers
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
Effects of Testosterone Treatment in Older Men
|New England Journal of Medicine|2016|864